Abstract: The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics.

Abstract: The present invention is directed to novel drug delivery devices and pharmaceutical compositions containing growth and differentiation factor proteins. Said devices and compositions are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. The invention is especially useful for the supportive therapy of diabetic wounds and ulcers.

Abstract: The present invention is directed to novel formulations and methods for the improved delivery and administration of hydrophobic therapeutic compounds that are substantially insoluble and/or susceptible to precipitation in aqueous solution at physiological pH, including, e.g., growth and differentiation factor-5 and related proteins. Many therapeutic compounds are hydrophobic at physiological pH levels.

Abstract: The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics.

Abstract: The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics.

Abstract: The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity.

Abstract: The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity.

Abstract: The present invention is directed to GDF-5 related proteins having an improved capability of inducing cartilage formation and a reduced capability of inducing bone formation. The novel proteins are particularly useful in the treatment of cartilage defects, wherein the formation of bone tissue is undesirable.

Abstract: This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. The compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The compositions can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.

Abstract: The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics.

Abstract: This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. Said compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as for example growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The invention can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.

Abstract: This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g., improved solubility and controlled release characteristics under physiological conditions. Compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects, such as growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g., bone, cartilage, tendons, ligaments, nerves and skin. These compositions can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.

Abstract: The application relates to novel biosynthetic growth factor mutants, derived from GDF-5, which exhibit improved biological activity. Mutations at positions 453 and 456 of human GDF-5 are disclosed, as well as use of these mutants in therapy of diseases associated with tissue degeneration/destruction.

Abstract: A process for the production of a purified recombinant GDF-5 related protein in prokaryotes comprises the steps of bacterial cell disruption and inclusion body solubilization to obtain a solubilized monomer of a GDF-5 related protein, said process characterized by a) disruption of bacterial cells with a high pressure homogenizer at a disruption pressure between 800 and 900 bar; and/or b) treatment of the recovered inclusion bodies with a denaturing solubilization buffer comprising L-arginine.

Abstract: The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic proteins, wherein depending on the subject matter the proteins may be dimeric or monomeric proteins. The osteoinductive materials according to the present invention have improved properties. The invention further concerns methods for producing the respective improved osteoinductive materials.

Abstract: A protein having amino acid sequence in SEQ ID No.:1 of the Sequence Listing derived from human MP52, and a dimer protein thereof. A homodimer protein described above can be obtained by constructing a plasmid containing DNA coding amino acid sequence in SEQ ID No.:1 of the Sequence Listing with a methionine at the N-terminus, introducing the plasmid into E. coli for transformation, solubilizing inclusion bodies obtained by culturing the transformant, purifying the monomer protein from the solubilized solution, refolding the monomer protein into a dimer protein and purifying the same. The homodimer protein described above is useful as a pharmaceutical composition for treating cartilage and bone diseases.

Abstract: The present invention is directed to novel formulations and methods for the improved delivery and administration of hydrophobic therapeutic compounds that are substantially insoluble and/or susceptible to precipitation in aqueous solution at physiological pH, including, e.g., growth and differentiation factor-5 and related proteins. Many therapeutic compounds are hydrophobic at physiological pH levels.

Abstract: The present invention is directed to novel methods and compositions containing growth factor proteins. Said compositions are specifically designed to optimize the amount of crucial structural elements of mammalian tissues. The invention is especially useful for the preservation and improvement of dermal tissue appearance.

Abstract: The invention concerns a protein of the TGF-? family, the DNA coding therefor and a pharmaceutical composition containing the protein.

Abstract: A protein having amino acid sequence in SEQ ID No.:1 of the Sequence Listing derived from human MP52, and a dimer protein thereof. A homodimer protein described above can be obtained by constructing a plasmid containing DNA coding amino acid sequence in SEQ ID No.:1 of the Sequence Listing with a methionine at the N-terminus, introducing the plasmid into E. coli for transformation, solubilizing inclusion bodies obtained by culturing the transformant, purifying the monomer protein from the solubilized solution, refolding the monomer protein into a dimer protein and purifying the same. The homodimer protein described above is useful as a pharmaceutical composition for treating cartilage and bone diseases.